MMV 390048

Drug Profile

MMV 390048

Alternative Names: MMV 048; MMV390048

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Griffith University; University of Cape Town
  • Developer Medicines for Malaria Venture; Technology Innovation Agency; University of Cape Town
  • Class Aminopyridines; Antimalarials; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malaria

Most Recent Events

  • 01 Sep 2016 Medicines for Malaria Venture plans a phase II trial for Malaria in Ethiopia (NCT02880241)
  • 01 May 2016 Phase I/II clinical trials in Malaria (In volunteers) in Australia (PO, Tablet) (NCT02783833)
  • 01 May 2016 Phase-I clinical trials in Malaria (In volunteers) in Australia (PO, Tablet) (NCT02783820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top